Harbin Gloria Pharmaceuticals (002437) — Free Cash Flow Generation Index
Harbin Gloria Pharmaceuticals (002437) has a Free Cash Flow Generation Index of 0.98x as of September 2025. Free cash flow of CN¥178.63 Million represents 1% of operating cash flow (CN¥182.89 Million). Explore 002437 capex reinvestment rate to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Harbin Gloria Pharmaceuticals Free Cash Flow Generation Index (2007–2025)
Historical FCF Generation Index trend for Harbin Gloria Pharmaceuticals across 19 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Harbin Gloria Pharmaceuticals.
Annual Free Cash Flow Generation for Harbin Gloria Pharmaceuticals (2007–2025)
Year-by-year Free Cash Flow Generation Index for Harbin Gloria Pharmaceuticals. Check Harbin Gloria Pharmaceuticals cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (CNY) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.91x | CN¥249.54 Million | CN¥273.36 Million | CN¥23.81 Million | ▲ +7.8% |
| 2024 | 0.85x | CN¥348.04 Million | CN¥410.94 Million | CN¥62.90 Million | ▼ -5.0% |
| 2023 | 0.89x | CN¥244.55 Million | CN¥274.18 Million | CN¥29.62 Million | ▲ +2.1% |
| 2022 | 0.87x | CN¥228.60 Million | CN¥261.62 Million | CN¥33.01 Million | ▼ 0.0% |
| 2021 | 0.87x | CN¥239.67 Million | CN¥274.18 Million | CN¥34.51 Million | ▲ +136.1% |
| 2020 | -2.42x | CN¥-30.90 Million | CN¥12.76 Million | CN¥43.66 Million | ▼ -362.9% |
| 2019 | 0.92x | CN¥561.94 Million | CN¥610.37 Million | CN¥48.43 Million | ▲ +1.1% |
| 2018 | 0.91x | CN¥1.06 Billion | CN¥1.16 Billion | CN¥104.34 Million | ▲ +29.8% |
| 2017 | 0.70x | CN¥457.16 Million | CN¥651.80 Million | CN¥194.63 Million | ▼ -14.7% |
| 2016 | 0.82x | CN¥855.14 Million | CN¥1.04 Billion | CN¥185.34 Million | ▲ +37.7% |
| 2015 | 0.60x | CN¥418.95 Million | CN¥702.05 Million | CN¥283.10 Million | ▼ -26.6% |
| 2014 | 0.81x | CN¥548.14 Million | CN¥674.04 Million | CN¥125.89 Million | ▲ +27.2% |
| 2013 | 0.64x | CN¥289.67 Million | CN¥453.02 Million | CN¥163.35 Million | ▲ +114.0% |
| 2012 | 0.30x | CN¥61.52 Million | CN¥205.89 Million | CN¥144.37 Million | ▲ +200.3% |
| 2011 | -0.30x | CN¥-38.30 Million | CN¥128.61 Million | CN¥166.90 Million | ▲ +73.9% |
| 2010 | -1.14x | CN¥-128.29 Million | CN¥112.59 Million | CN¥240.88 Million | ▼ -278.0% |
| 2009 | 0.64x | CN¥109.34 Million | CN¥170.82 Million | CN¥61.47 Million | ▲ +87.5% |
| 2008 | 0.34x | CN¥19.73 Million | CN¥57.81 Million | CN¥38.08 Million | ▼ -54.4% |
| 2007 | 0.75x | CN¥39.09 Million | CN¥52.26 Million | CN¥13.17 Million | — |